复发或难治性多发性骨髓瘤患者的达雷妥尤单抗三联疗法：“真实世界”经验
Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A "real world" experience.
作者信息
Fucci Ludovica, Gensini Lorenzo, Coppetelli Ugo, La Barbera Elettra Ortu, Gentile Martina, Fiori Luciano, Perrone Salvatore, Cimino Giuseppe
机构信息
Department of Translational and Precision Medicine, University of Rome "La Sapienza", Viale dell'Università, 37, Roma 00185, Italy.
Hematology and Transplant Unit, Santa Maria Goretti Hospital, AUSL, Latina, Italy.
出版信息
Leuk Res Rep. 2022 May 30;17:100330. doi: 10.1016/j.lrr.2022.100330. eCollection 2022.
We report our retrospective analysis on 34 relapsed/refractory multiple myeloma (RRMM) patients treated with daratumumab based triplets. Twenty patients were females and 14 males. Median age was 73.2. Daratumumab was associated to lenalidomide in and dexamethasone (DRd) in 30 (88,3%) and to bortezomib and dexamethasone (DVd) in 4 cases (11,7%). The ORR was 88%. CR occurred in 12% of cases, VGPR in 44% and PR in 32%. The 12 months PFS and OS rates were 78% and 86,5%, respectively. Present data confirm those recently reported in the literature and further reinforce the early use of daratumumab-based triplets for RRMM patients.
我们报告了对34例接受基于达雷妥尤单抗的三联方案治疗的复发/难治性多发性骨髓瘤（RRMM）患者的回顾性分析。其中20例为女性，14例为男性。中位年龄为73.2岁。30例（88.3%）患者接受达雷妥尤单抗联合来那度胺和地塞米松（DRd）治疗，4例（11.7%）患者接受达雷妥尤单抗联合硼替佐米和地塞米松（DVd）治疗。客观缓解率（ORR）为88%。完全缓解（CR）发生率为12%，非常好的部分缓解（VGPR）为44%，部分缓解（PR）为32%。12个月的无进展生存期（PFS）和总生存期（OS）率分别为78%和86.5%。目前的数据证实了最近文献报道的结果，并进一步支持RRMM患者早期使用基于达雷妥尤单抗的三联方案。
Zotero 插件